Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.19.3
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 12,277 $ 7,836 $ 31,431 $ 19,333
Collaboration and License Agreements and Supply Agreements        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 12,277 7,836 31,431 19,333
Collaboration and License Agreements and Supply Agreements | Celgene        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 3,354 1,990 6,599 8,909
Collaboration and License Agreements and Supply Agreements | Merck        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 5,488 3,514 15,620 3,514
Collaboration and License Agreements and Supply Agreements | SutroVax        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 786 582 1,067 1,484
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany “EMD Serono”)        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 2,649 $ 1,750 $ 8,145 $ 5,426